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A B S T R A C T
The aim of the present study was to develop an optimized niosome formulation for the encapsulation of a poorly
water-soluble drug by the ecological probe sonication method. Pluronic L121 and Span 60 were used as surface
active agents and the optimization of the composition was made with the aid of Design of Experiment (DoE)
concept. Rifampicin was used as a model drug. Concentration levels of charge inducing agent, dicetylphosphate
(DCP), and Pluronic L121 were studied as variables. Prepared niosomes with varying concentrations of DCP and
Pluronic L121 resulted in small sized niosomes with sizes ranging from 190 nm to 893 nm. During the four weeks
stability testing, the particle sizes were reduced slightly. The formulation containing 2mg of DCP resulted in
most stable niosomes with 75.37% entrapment efficiency. All the niosomal formulations showed higher in vitro
drug release rates as compared to bulk drug formulation. As a conclusion, rifampicin loaded niosomes prepared
with Pluronic L121 and Span 60 resulted in stable, small sized niosomes with improved drug release profile.
1. Introduction
Niosomes are self-organizing non-ionic surfactant vesicles, which
encapsulate aqueous volume of drug(s) with or without the addition of
cholesterol and other lipid contents [1,2]. Niosomes have the capability
to encapsulate both lipophilic and hydrophilic drugs [3]. They are al-
ternative to liposomes, and their main benefits as compared to lipo-
somes are their lower price, higher stability and better biodegradability
[4]. By making niosomes, the side effects of drugs have been reduced
and the therapeutic efficacy has been increased [5]. More than 50
different drugs have been encapsulated into niosomes and administered
via oral, nasal, ophthalmic, inhalation and parenteral routes [6].
The arrangement of non-ionic surfactants in bilayer or micellar form
depends on the hydrophilic-lipophilic balance (HLB) of the surfactants.
The properties of drug, other membrane additives, and the method of
manufacturing also influence the structure and behavior of niosomes
[7,8]. Hydrophilic drugs are surrounded by the bilayer of amphiphiles,
while hydrophobic drugs are entrapped within the bilayer of vesicles
[9]. A number of non-ionic surfactants are used for production of nio-
somes, such as polysorbates, alkyl ethers, alkyl amides and alkyl esters,
but in many studies only a single surfactant is used [10–13]. However,
if a mixture of two or more surfactants are used, stable, small and
monodisperse niosomes can be reached [10]. Poloxamers are widely
utilized pharmaceutical excipients, though they are less studied in
formulating niosomes. They are well known to improve the solubility of
poorly soluble drugs via solubilization effect [14,15] and they are also
functioning as permeation enhancers [16], and hence, good candidates
for excipients in niosomal formulations.
Niosomes are prepared by different methods, including thin film
rehydration, reverse phase evaporation, and ether injection methods
[17,18]. These methods require removal of organic solvents and they
are expensive and time consuming. To overcome these problems, probe
sonication method has been developed [19]. Probe sonication tech-
nique is an eco-friendly green technique with no addition of organic
solvents. Besides, it is a simple and low cost technique. In this method,
only aqueous phase of drug is mixed with surfactant, cholesterol and
other surface additives, and subjected to ultra-sonication with a probe
[19]. In an earlier study, where probe sonication and thin film hydra-
tion techniques were compared, both the production techniques pro-
duced spherical vesicles [19]. Further, niosomes produced by probe
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sonication technique were smaller with higher monodispersity having
faster drug release rates as compared to niosomes produced by tradi-
tional technique.
As already mentioned, both hydrophilic and hydrophobic drugs can
be encapsulated inside the niosomal structures, but poorly soluble hy-
drophobic drugs are mostly benefitting niosomal formulations. An ex-
ample of group of drugs, which are good candidates for niosomal drug
delivery, are drugs that benefit for targeted and sustained drug release,
such as chemotherapeutic agents used for treatments of different type of
cancers [20]. The challenge to deliver these kind of drugs in the body is
their toxic side effects, poor water solubility and drug resistance [21].
To overcome these problems, niosomes are designed by optimum
combination of non-ionic surfactants to increase the solubility, bioa-
vailability, reduction in toxicity and increased residence time in blood
circulation [22–24].
The aim of the present study was to improve the drug release profile
of a poorly soluble drug by making a niosomal formulation with less
utilized environmental friendly and cost efficient probe sonication
method. Rifampicin was used as a model drug. Rifampicin is a
Biopharmaceutics Classification System (BCS) class II antitubercular/
antimicrobial drug and it inhibits the RNA polymerase enzyme [14–18].
Due to low solubility, polymorphism and degradation in gastric fluids,
rifampicin is poorly bioavailable [19]. In order to improve the perfor-
mance of the niosomes, a combination of Span 60 and Pluronic L121
was used for the production of niosomes. A mixture of two surfactants
were selected to be used in this study, because the presence of two
different surfactants has been shown to be able to improve the prop-
erties of the niosomes [10,19]. Pluronic L121 was selected based on its
capability to increase solubilization and permeation of poorly soluble
drugs. With the aid of factorial design, the composition of niosomal
formulations was optimized.
2. Materials and methods
2.1. Materials
Rifampicin (Orion Pharma, Finland) was used as a model poorly
water-soluble drug. Sorbitan monostearate (Span 60, Sigma-Aldrich,
USA) and PEO-PPO-PEO copolymer (polyethylene oxide-polypropylene
oxide-polyethylene oxide copolymer, Pluronic L121, Mn 4400, Sigma-
Aldrich, USA) were used as membrane formers in niosomes. Cholesterol
(Sigma-Aldrich, USA) was used as membrane stabilizer and dicetyl-
phosphate (DCP, Sigma-Aldrich, USA) as charge tailoring agent.
Disodium hydrogen phosphate, potassium dihydrogen phosphate and
sodium chloride (all from Sigma-Aldrich, USA) were needed for buffer
solutions. Dialysis membranes (Spectra/Por MWCO: 8–10 kD, Sigma-
Aldrich, USA) were utilized for drug release testing. Water used in all
the tests was Milli-Q water (Millipore, Merckmillipore, USA).
2.2. Methods
2.2.1. Preparation of rifampicin niosomes
For production of niosomes by probe sonication method [19], ri-
fampicin was first mixed with 15mL of water with the help of magnetic
stirrer, after which cholesterol, Span 60, Pluronic L121 and DCP were
added. The amount of Pluronic L121 and DCP were the variables in the
optimization of the niosome production. Based on the preliminary
studies, 290mg of Pluronic L121 and 1mg of DCP was selected as a
central point for the central composite design. In the factorial design,
three different levels of the variables was used: amount of Pluronic
L121 was 246, 290 or 334mg, and amount of DCP 0, 1 or 2mg. The
exact compositions of studied batches are presented in Table 1. The
mixture was then subjected to probe sonication (Vibra Cell, Sonics &
Materials, Inc., USA) for 5min at 57 °C of probe temperature in a pul-
satile manner (50 s sonication with 10 s pause) with 30% amplitude.
After probe sonication, niosomes were collected and stored at 4 °C for
physicochemical characterization.
2.2.2. Attenuated Total Reflectance-Fourier Transform Infrared (ATR-
FTIR) spectroscopy
The possible interactions between the drug, non-ionic surfactants
and membrane additives were studied by Attenuated Total Reflectance -
Fourier Transform Infrared (ATR-FTIR) spectroscopy. The ATR-FTIR
analysis of all the individual components, physical mixture and one
niosome formulation were performed. The spectra were collected by
using FTIR spectrophotometer (Bruker Optics, Germany) with an ad-
ditional horizontal accessory of ATR (MIRacle, Pike Technology, Inc.,
Germany). Spectral range from wavenumber (400-4500 cm−1) was
used with a 4 cm−1 resolution by using (OPUS 5.5) software with no
spectral pretreatment at an ambient temperature [10,25]. The re-
producibility of the technique was ensured by making triplicate sepa-
rate measurements from one single sample.
2.2.3. Thermal analysis
The physical state of the rifampicin in the selected formulation was
estimated by using Differential Scanning Calorimetry (DSC 823e,
Mettler Toledo, USA). Pure rifampicin, individual niosome constituents,
physical mixture and selected formulation were accurately weighed
(3–5mg) in an aluminium pan and the pan was closed. The thermal
scanning was carried out at 5 °C/min and heated from 25 °C to 260 °C.
The scans were recorded under the flow of nitrogen gas at a rate of
50mL/min. Indium was used as a reference standard for the DSC
equipment.
2.2.4. Drug entrapment efficiency
For determining the drug entrapment efficiency, the formulations
were ultracentrifuged at 28000 rpm for 1 h at 4 °C (Beckman Coulter,
Optima LE-80K, USA). The supernatant was collected, the pellet at the
bottom of the centrifuge tube was washed twice with water, water was
collected and centrifugation was repeated. Drug concentration in the
aqueous solution containing supernatants and water used for washing
was determined. The percentage entrapment efficiency (EE%) of ri-
fampicin was calculated by the following equation (Equation (1)) [26]:
EE%= [(Qt - Qr)/Qt] x 100, (1)
Where Qt is the amount of drug initially used for the preparation of
niosomes and Qr is the amount of drug present in supernatant after
centrifugation.
2.2.5. Differential light scattering measurement
The diameter of the niosomes (z-average), polydispersity index
(PDI) and zeta potential were measured for all the formulations using
Zetasizer Nano ZS (Malvern Instruments Ltd., USA). The niosomal dis-
persions (20 μL) were diluted with water (15mL) before the measure-
ment to avoid multi scattering phenomenon. All the measurements
were performed in triplicates.
2.2.6. Transmission electron microscopy
The morphology of the niosomes was analyzed by the transmission
electron microscopy (TEM, Jeol JEM-1400, Jeol Ltd, Japan) using an
acceleration voltage of 80 kV. For the sample preparation, niosomal
dispersions were negatively stained with freshly prepared 2% uranyl
acetate solution, mounted on a carbon-coated copper grid, and air-dried
before analysis.
2.2.7. Stability studies
The stability of niosome formulations was determined by storing the
niosomal dispersions in sealed 20mL glass vials at 4 °C in refrigerator.
The size, PDI and zeta potential values of the stored formulations were
evaluated at predefined time intervals (0, 1, 2, 3 and 4 weeks after
preparation). Besides this, visual examination about the physical
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changes was also done.
2.2.8. Drug release studies
The drug release studies were carried out at phosphate buffer pH 7.4
solution in a vessel using a magnetic stirrer. For the dissolution study,
dialysis membrane was soaked in water for 24 h prior the testing. Just
before the dissolution tests, the aqueous dispersions of the formulations
(1 mL) were poured inside the dialysis membrane, clamped and put into
the dissolution vessel. The study was carried out at 37 °C, the amount of
the medium was 350mL, and stirring speed was 100 rpm. The aliquots
were sampled at predefined time intervals (0, 15 min, 30min, 45 min,
60 min, 75min, 105min, 2.5 h, 4 h, 5.5 h, 8 h, 10 h, 12 h) and re-
plenished with the same amount of fresh buffer. Samples withdrawn
from the dissolution media were analyzed on the UV–Vis spectro-
photometer (UVe1600PC, VWR Int. bvba, China) at a wavelength of
475 nm.
3. Results and discussion
3.1. Physical characterization of niosomes
Rifampicin loaded niosomes were prepared with the combination of
surfactants Span 60 and Pluronic L121. All the formulations of nio-
somes were containing equal quantities of Span 60, cholesterol and
drug. By changing the quantities of Pluronic L121 and DCP, the com-
position for optimized formulation was determined. Three different
levels of these two parameters were studied in the central composite
design. The optimization of the process was performed based on the
critical quality attributes (CQAs). Selected CQAs for niosomal for-
mulations were small size (size below 350 nm), low PDI (< 0.5) and
negative zeta potential (<−25mV). The value of PDI less than 0.5 is
considered to have low polydispersity and low/no aggregation [9]. The
zeta potential is related to the stability of the niosomes and it is due to
the addition of DCP as a membrane additive. The absolute values of zeta
potential close to 30mV or higher are considered more stable due to the
electrostatic repulsive forces [9].
As has been shown in previous studies, the addition of cholesterol
gives rigid, stable and intact niosome structures with low PDI value,
while, without cholesterol, formulations have gel like appearance [27].
Span 60 leads to stable and large sized niosomes with maximum en-
trapment efficiency, and the high HLB value (more than 11) hinders the
formation of vesicles [28]. The poorly water-soluble drugs are en-
trapped efficiently by Pluronic L121 and it leads to low PDI value as
well as more stable vesicular niosomes [29–31]. The membrane ad-
ditive DCP is a negative imparting agent, which reduces the aggregation
tendency due to significant interparticle electric repulsion and it helps
to formulate monodisperse niosomes with low PDI value [32]. Ac-
cordingly, in this study the amount of Pluronic L121 and DCP were the
variables for the factorial design in order to optimize the composition
based on CQAs.
First, formulations without the drug were produced, in order to find
the central point for the composition design (RA1), and when the for-
mulation filled the CQA criteria, model drug was added to the com-
position, and the central composite design model was formed (Table 1).
Based on the preliminary screening studies, niosomes containing
290mg of Pluronic L121 and 1mg of DCP fulfilled all the CQA criteria,
and hence this composition was selected as a central point for the
factorial design (RA1).
The particle size information, PDI values and zeta potentials of
different studied formulation are shown in Table 2. The particle size in
all the formulations ranged between 193 nm and 893 nm and PDI va-
lues were from 0.38 to 0.72. All the drug containing formulations ful-
filled the particle size requirement of CQAs: the particle sizes ranged
from 205 nm to 350 nm. The largest particle size was reached with the
composition having lowest amount of DCP (RA10), and the smallest
particles were formed with the lowest amount of Pluronic L121. The
center point with the drug (RA2) showed PDI value a little above the
CQA value, but all the other drug containing compositions showed
acceptable PDI values. Differences in size and PDI between the un-
loaded and drug loaded niosomes were small, except with the highest
Pluronic L121 concentration (RA5 vs. RA6).
TEM image of the optimized formulation is shown in Fig. 1. Based
on the TEM image, niosomes have well defined spherical shape with a
definite wall enclosing aqueous core. Moreover, the mean niosome size
from TEM analysis was in a good agreement with that obtained by DLS
experiment.
The stability of the niosomal formulations at 4 °C was studied by
monitoring the changes in the particle size, PDI and zeta potential va-
lues. After one week of storage, size and PDI values were slightly
lowered. The formulations showed zeta potential values between
−27mV and −39mV (Table 2). High absolute zeta potential values in
all the formulations indicated good stability. During the storage time of
one month at the 4 °C, only minor changes in zeta potential values as
well as in particle size and PDI values were observed, indicating good
stability of all the studied niosomal formulations.
Table 1
Composition of different niosome formulations.
Formulations Span 60 (mg) Pluronic L121 (mg) Cholesterol (mg) DCP (mg) Drug (mg) Milli-Q H2O (ml)
RA1 43 290 77.3 1 – 15
RA2 43 290 77.3 1 10 15
RA3 43 246 77.3 1 – 15
RA4 43 246 77.3 1 10 15
RA5 43 334 77.3 1 – 15
RA6 43 334 77.3 1 10 15
RA7 43 290 77.3 2 – 15
RA8 43 290 77.3 2 10 15
RA9 43 290 77.3 0 – 15
RA10 43 290 77.3 0 10 15
Table 2
Size, PDI, zeta-potential and entrapment efficiency values of different niosomal
formulations.
Formulations Size average (nm) PDI Charge (mV) EE%
RA1 195.6 ± 12.8 0.492 ± 0.047 −27.5 ± 0.9 –
RA2 314.8 ± 23.9 0.548 ± 0.087 −32.0 ± 0.1 73.38%
RA3 300.5 ± 36.6 0.448 ± 0.034 −38.8 ± 0.3 –
RA4 205.6 ± 10.0 0.482 ± 0.034 −35.6 ± 1.7 71.13%
RA5 893.6 ± 135.5 0.725 ± 0.117 −39.9 ± 5.2 –
RA6 297.8 ± 2.4 0.387 ± 0.005 −36.0 ± 0.5 65.64%
RA7 236.3 ± 36.0 0.391 ± 0.105 −27.5 ± 0.9 –
RA8 255.3 ± 24.6 0.381 ± 0.053 −37.6 ± 1.0 75.37%
RA9 443.5 ± 86.7 0.469 ± 0.037 −34.9 ± 3.4 –
RA10 350.8 ± 62.3 0.481 ± 0.072 −35.5 ± 0.7 80.11%
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3.2. Drug entrapment efficiency (EE%)
Entrapment efficiency is an important factor that depicts the for-
mulation characteristics of niosomes. In this study, the entrapment ef-
ficiency of the formulations was increased from 71.13% to 73.38% as
the amount of Pluronic L121 was increased (from 246 to 290mg), but
the difference was very small. And, at the same time, particle size was
increased from ca. 205 nm–315 nm. Accordingly, it is difficult to say if
the amount of Pluronic L121 or the change in particle size has more
impact on the entrapment efficiency. With small particle systems it is
typical that the increase in particle size also increases the entrapment
efficiency. When the Pluronic L121 amount was further increased (to
334mg) the entrapment efficiency was decreased (65.64%), but the
particle size was kept quite constant. The critical micelle concentration
(CMC) of Pluronic L121 is 0.0004 (wt%), so its concentration in all the
formulations were above the CMC [33]. However, when the Pluronic
concentration was the highest, the increased solubilization tendency of
Pluronic L121 resulted that more rifampicin was soluble in aqueous
media, which was reflected by the lowered entrapment efficiency
[9,29].
When considering the impact of DCP, formulation without DCP
showed maximum entrapment efficiency (80.11%). As the DCP con-
centration was increased (1mg) the entrapment efficiency decreased,
but further increase in the concentration of DCP (2mg) increased the
entrapment efficiency as indicated in Table 2. Again, the highest en-
trapment efficiency was reached with largest particle size (ca. 350 nm),
which might have been the main reason behind this behavior instead of
the changes in the amount of DCP. Accordingly, the amount of DCP
alone is not directly responsible for the behavior and these parameters
need to be looked in combination.
3.3. Interaction studies
The ATR-FTIR study has a major role in pharmaceutical compat-
ibility assessment of all the ingredients used in the formulation devel-
opment. The technique is used as a pre-formulation study for the de-
velopment of products. The ATR-FTIR spectra of rifampicin and all the
excipients individually, the physical mixture of the optimized for-
mulation and corresponding optimized niosomal formulation are shown
in Fig. 2.
Rifampicin as a pure drug showed the characteristic band peak at
1713 cm−1 due to acetyl group and 1733 cm−1 due to furanone C]O.
Vibration on a broad band 3565-3150 cm−1 due to eOH, 1566 cm−1
due to amide C]O and 2883 cm−1 due to NeCH3 groups [34]. Span 60
showed the peaks at 2916.75 cm−1 (eOH stretch, broad),
2849.58 cm−1 (eOH stretch, broad), a cyclic 5-membered ring peak at
1734.65 cm−1 and small peaks from 1000 to 1200 cm−1 due to
aliphatic groups [35]. Pluronic L121 showed the peak stretch at
2990 cm−1 of as asymmetrical methyl CeH, scissoring of CeH bondage
at 1480 cm−1, symmetrical CeH bond at 1387 cm−1 and at 1120 cm−1
an ether linkage (CeOeC) [36]. Cholesterol showed the ATR-FTIR
peaks at 2931.41 cm−1, 2866.83 cm−1, 1770.20 cm−1, and
1055.17 cm−1 due to (acetyl group, symmetric eCH3, vinyl group and
ReO group) respectively [25].
The ATR-FTIR spectra of physical mixture of the optimized for-
mulation and niosomes of the same formulation were evaluated for
identifying any changes in peaks or peak shifts indicating interactions
in the formulation (Fig. 2). The spectra of physical mixture of the for-
mulation and optimized niosomes were similar and they both showed
diffusion of the peaks. In earlier studies with Spans and cholesterol, it
has been found out that membrane stabilization in niosomes is based on
interactions between the glycerol oxygen in Spans and β-OH group in
cholesterol, which was causing changes in the spectra [19,37]. Char-
acteristic spectral features of the drug were not seen in the spectra of
physical mixture or niosomes. The relative drug amount in these sam-
ples were very low, and it is possible that the concentration in the
mixture is below the detection limit, and/or overlapping events are
disturbing the analysis.
In thermal analysis, Span 60, DCP, cholesterol and rifampicin
showed their characteristic melting endotherm at 54 °C, 78 °C, 150 °C,
and 182 °C, respectively, as shown in Fig. 3. The physical mixture
showed a slightly broader peak at 57 °C indicating the slight interaction
between the Span 60 and cholesterol [37]. The niosome formulation
indicated extra peaks between the 79 °C- 107 °C indicating material
interactions. These interactions increased the stability and rigidity of
the vesicular bilayer in niosomes, which was seen also in considerably
high entrapment efficiency values as well as in enhanced storage sta-
bility.
No rifampicin melting peak or shift in the baseline due to Tg of
amorphous drug was seen in the physical mixture nor in the prepared
niosomes. The drug amount in the composition was low, which could
be one reason for that these events are not seen in the thermograms, or
drug might have formed molecular level mixtures with excipient(s).
However, based on the results, it is impossible to confirm which was the
case. Molecular level mixtures can increase the entrapment efficiency
values, and physical form of the drug inside the niosomes is important
because it can influence the in-vitro and in-vivo release patterns of the
drug [38].
Fig. 1. TEM image of the optimized niosomal formulation.
Fig. 2. ATR-FTIR spectra of pure materials, physical mixtures and optimized
niosomes.
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3.4. Stability studies
The storage stability at 4 °C of all the niosome formulations with or
without drug was studied for a period of 1 month (Table 3). After one
week of storage time, formulations RA6 containing highest amount of
Pluronic L121 and RA10 with highest amount of DCP resulted in
slightly reduced niosome size. All the other drug loaded niosomes in-
creased in size during the first week of storage. This kind of behavior is
typical for niosomes. When the sonication stress is over, e.g. after one
week of storage, niosomes are relaxed and they become fully matured
due to which particle size reaches the stable final value [10].
After the first week, all the formulations tended to reduce in size.
The formulation RA7 of empty niosomes and corresponding drug
loaded formulation RA8 showed the best results, small stable particle
size with low PDI value throughout the 1-month storage period. The
formulations RA7 without drug and RA8 with rifampicin contained
high concentration of DCP (2mg, Table 3). With these niosomes (RA7 vs
RA8), addition of the drug to the composition clearly increased the
particle size, same kind of behavior was also seen with the central point
(RA1 vs RA2) composition.
PDI values of all the freshly prepared formulations were less than
0.5 except formulation RA5 (0.725). After one week, the PDIs of all the
formulations were reduced, though PDI of RA5 was still slightly higher
than 0.5. The formulations RA7 (without rifampicin) and RA8 (with
rifampicin) showed most stable and low PDI values during the storage
indicating good stability.
If the zeta-potential of niosomes are close to or below −30mV,
particles are quite stable due to interparticle repulsive forces, which are
able to prevent particle aggregation. All the formulations in this study
showed negative zeta-potentials close to or below −30mV, and the
differences in zeta-potential values were small. Accordingly, based on
zeta-potential values there were no big differences between the dif-
ferent formulations.
3.5. Drug release studies
The dissolution studies of all the rifampicin loaded formulations and
control (pure rifampicin drug) was carried out in phosphate buffer
saline pH 7.4 (Fig. 4). A burst release of drug from all the niosome
formulations was seen in the beginning of the dissolution testing, which
was caused by the presence of Pluronic L121 [39]. It has been reported
previously that Pluronic L121 has good solubilization behavior due to
which the dissolution rate of the niosomal formulations increased when
compared with pure drug [35]. The drug release profiles from all the
niosomal formulations were similar during the first 2 h of drug release
testing. After the first 2 h, the drug release increased following the
order: RA6 < RA10 < RA4 < RA8 < RA2 with the percentages
61.69%, 62.75%, 66.84%, 70.78% and 75.90%, respectively, drug re-
leased within 12 h. The pure drug released 32.43% at the same time
period.
While the presence of Pluronic L121 increased the drug release in all
the niosomal formulations, effect of its relative amount on the drug
release was not that clear: with the highest amount of Pluronic L121
(334mg), the formulation RA6 showed least drug released, and the
formulation (RA4) with lowest amount of Pluronic L121 (246mg)
showed comparatively more drug release. Highest drug release value
(75.90%) was reached with the formulation RA2, which contained
290mg Pluronic L121. Formulation RA10 without DCP and RA8 with
highest amount of DCP (2mg) released 62.75% and 70.78%, respec-
tively.
Particle sizes of the different drug loaded niosomal formulations
were from 205 to 350 nm; it is well known from literature that particle
size is also affecting the drug release behavior, as well as the drug
loading level in the formulations. The high concentration of cholesterol
results in more rigid niosomes and DCP as a charge tailoring agent is
changing the electrical properties of niosomes, which can have im-
pacted on the interactions as well as drug release behavior.
Formulations releasing highest amount of drug after 12 h drug re-
lease testing, RA2 and RA8, were both containing 290mg of Pluronic
L121. The amount of DCP was 1mg in RA2 and 2mg in RA8. Their
particle sizes (315 and 255 nm) and entrapment efficiencies (73 and
75%) had intermediate-level values. Accordingly, as discussed before,
the faster dissolution rate was not caused by a single factor, but it was
more combined effect.
Fig. 3. DSC thermograms of pure materials, physical mixtures and optimized niosome formulation.
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4. Conclusion
In the present study, the poorly water-soluble drug, rifampicin as a
model drug, was encapsulated inside the niosomes. The core of nio-
somes was produced with Span 60 and varying concentrations of
Pluronic L121 and dicetylphosphate (DCP). Both two variables, the
amounts of Pluronic L121 and DCP, had some impact on the properties
of the formed niosomes, but all the prepared drug loaded formulations
still showed reasonable drug entrapment efficiency, acceptable size,
good stability and higher dissolution profile as compared to bulk drug
formulation. Based on the study, the use of Span 60 and Pluronic L121
in combination for the preparation of niosomes are a promising po-
tential carrier system for the encapsulation of poorly soluble drugs for
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